References

(1) World Health Organization. Global Tuberculosis Control 2009: surveillance, planning, financing: WHO Report 2009. 2009. Geneva, World Health Organization (WHO/HTM/TB/2009.393).

(2) Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC for the WHO Global Surveillance and Monitoring Project. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. *Journal of the American Medical Association* 1999; 282:677-686.

(3) World Health Organization. Resolution WHA44.8. Tuberculosis control programme. Handbook of resolutions and decisions of the World Health Assembly and the Executive Board (WHA44/1991/REC/1). Third ed. Geneva: World Health Organization; 1993.

(4) Dye C, Maher D, Weil D, Espinal M, Raviglione M. Targets for global tuberculosis control. *International Journal of Tuberculosis and Lung Disease* 2006; 10:460-462.

(5) World Health Organization. The Stop TB Strategy: Building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/TB/2006.368, 1-24. 2006.

(6) Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. *New England Journal of Medicine* 1989; 320(9):545-550.

(7) Centers for Disease Control and Prevention. Emergence of *Mycobacterium tuberculosis* with extensive resistance to second-line drugs - Worldwide, 2000-2004. *Morbidity and Mortality Weekly Report* 2006; 55(11):301-305.

(8) Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 2006; 368(9547):1575-1580.

(9) Evans CC. Historical background. In: Davies PDO, editor. Clinical tuberculosis. London: Chapman & Hall; 1998.

(10) ECDC. Tuberculosis Surveillance in Europe 2007. ECDC, Sweden, 2009

(11) Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in Western Europe. *Bulletin of the World Health Organization* 1993; 71(3-4):297-306.

(12) Snider DE, Roper WI. The new tuberculosis. *New England Journal of Medicine* 1992; 326:703-705.

(13) Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R et al. European framework for tuberculosis control and elimination in countries with a low incidence. *European Respiratory Journal* 2002; 19:765-775.

(14) Health Protection Agency Centre for Infections. Focus on tuberculosis: annual surveillance report 2006 - England, Wales and Northern Ireland. 2006. London, Health Protection Agency.

(15) Health Protection Agency Centre for Infections. Tuberculosis in the UK: Annual Report on Tuberculosis Surveillance and Control in the UK 2007. 1-11-2007. London, Health Protection Agency Centre for Infections.

(16) Department of Health. Stopping Tuberculosis in England: An Action Plan from the Chief Medical Officer. 2004. London, United Kingdom, Department of Health.

(17) Deeny J. History of tuberculosis in Ireland. In: Farmer T, editor. The end of an epidemic. Essays in Irish Public Health 1935-1965. Dublin: A & A Farmer; 1955. 99-112.

(18) Deeny J. Tuberculosis in Ireland: Report of the National Tuberculosis Survey (1950-1953). 1954. Dublin, Medical Research Council of Ireland.

(19) Health Protection Surveillance Centre. Report on the epidemiology of tuberculosis in Ireland 2006. 2008. Dublin, Health Protection Surveillance Centre.

(20) Health Protection Surveillance Centre. Report on the epidemiology of tuberculosis in Ireland 2005. 2007. Dublin, Health Protection Surveillance Centre.

(21) Department of Health and Children. Infectious Diseases (Amendment) (No.3) Regulations. S.I. No. 707 of 2003. Available at www.irishstatutebook.ie/front.html.

(22) National Disease Surveillance Centre. Case definitions for notifiable diseases. Infectious Disease (Amendment) (No. 3) Regulations 2003 (S.I. No. 707 of 2003). Dublin: National Disease Surveillance Centre; 2004.

(23) European Commission. 2008/426/EC: Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council (notified under document number C(2008) 1589) (Text with EEA relevance). *Official Journal of the European Communities 2008* 2008; 159(18/06/2008):46-90.

(24) World Health Organization. Definition of a new sputum smear positive TB case. 2-4-2007. Geneva, World Health Organization.

(25) Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care. 2006. The Hague, Tuberculosis Coalition for Technical Assistance.

(26) National Collaborating Centre for Chronic Conditions. Tuberculosis:clinical diagnosis and management of tuberculosis and measures for its prevention and control. 2006. London, Royal College of Physicians.

(27) Kennedy MP, O'Connor TM, Ryan C, Sheehan S, Bredin C. Nontuberculous mycobacteria: incidence in Southwest Ireland from 1987 to 2000. *Respiratory Medicine* 2003; 97(3):257-263.

(28) Menzies D. Interpretation of repeated tuberculin tests. *American Journal of Respiratory and Critical Care Medicine* 1999; 159:15-21.

(29) Comstock GW, Edwards LB, Philip RN, Winn WA. A comparison in the United States of America of two tuberculins, PPD-S and PPD-RT 23. *Bulletin of the World Health Organization* 1964; 31:161-170.

(30) Public Health Agency of Canada. Canadian Tuberculosis Standards 6th Edition. 2007. Canada, Public Health Agency of Canada.

(31) Schatz M, Patterson R, Kloner R, et al. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. *Ann Intern Med* 1976; 84(3):261-265.

(32) Statens Serum Institut. Product Specific Details for Tuberculin PPD RT 23 SSI, 2 T.U./0.1ml. 2006. Copenhagen, Denmark, Statens Serum Institut.

(33) Centers for Disease Control and Prevention. TB elimination; Tuberculin Skin Testing. 2007. Atlanta, Centers for Disease Control and Prevention, USA.

(34) American Thoracic Society and the Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. *American Journal of Critical Care Medicine* 2000; 161:5221-5247.

(35) Menzies RI, Vissandjee B, Amyot D. Factors associated with tuberculin reactivity among the foreign-born in Montreal. *American Review of Respiratory Disease* 1992; 146:752-756.

(36) Menzies D, Doherty MT. Diagnosis of latent TB infection. In: Reichmann LB, Hershfield ES, editors. Tuberculosis: A comprehensive international approach. Third ed. New York : Informa Healthcare USA; 2006.

(37) Menzies RI, Vissandjee B. Effect of Bacille Camille Guerin vaccination on tuberculin reactivity. *American Review of Respiratory Disease* 1992; 145:621-625.

(38) Menzies RI, Vissandjee B, Rocher I, St.Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. *Annals of Internal Medicine* 1994; 120:190-198.

(39) Bahr GM, Chugh TD, Bahbehani K, Shaaban MA, Abdul-Aty M, Al Shimali B et al. Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. *Tubercle* 1968; 68:105-112.

(40) Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculosis meningitis and miliary tuberculosis. A meta-analysis. *International Journal of Epidemiology* 1993; 22:1154-1158.

(41) Horwitz O, Bunch-Christensen K. Correlation between tuberculin sensitivity after 2 months and five years among BCG vaccinated subjects. *Bulletin of the World Health Organization* 1972; 47:49-58.

(42) Joncas JH, Robitaille R, Gauthier T. Interpretation of the PPD skin test in BCG vaccinated children. *Canadian Medical Association Journal* 1975; 113:127-128.

(43) Comstock GW, Edwards LB, Nabangwang H. Tuberculin sensitivity eight to fifteen years after BCG vaccination. *American Review of Respiratory Disease* 1971; 103:572-575.

(44) Hart P, Sutherland I, Thomas J. The immunity conferred by effective BCG and vole bacillus vaccines, in relation to individual variations induced tuberculin sensitivity and technical variations in the vaccines. *Tubercle* 1967; 48:201-210.

(45) Al-Kassimi FA, Al-Hajjaj MS, Al-Orainey IO, Bamgboye EA. Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? *American Journal of Respiratory Critical Care Medicine* 1995; 152:1575-1578.

(46) Fine P, Sterne J, Ponninghaus J, Rees R. Delayed type hypersensitivity, mycobacterial vaccines and protective immunity. *Lancet* 1994; 344:1245-1249.

(47) Comstock GW. Identification of an effective vaccine against tuberculosis. *American Review of Respiratory Disease* 1988; 138:479-480.

(48) Kardjito T, Donosepoetro M. The Mantoux test in tuberculosis:correlations between the diameters of the dermal responses and the serum protein levels. *Tubercle* 1981; 62:31-35.

(49) Stead WW, To T. The significance of the tuberculin skin test in elderly persons. *Ann Intern Med* 1987; 107:837-842.

(50) Guld J. Quantitative aspects of the intradermal tuberculin test in humans. *Acta Tuberc Scand* 1954; 30:26-36.

(51) Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis; recommendations from the National Tuberculosis Controllers Association and CDC. *Morbidity and Mortality Weekly Report* 2005; 54(No. RR-15):1-37.

(52) Ministry of Health. Guidelines for tuberculosis control in New Zealand 2003. 2003. Wellington, Ministry of Health.

(53) Anderson P, Munk ME, Pollock S, et al. Specific immune-based diagnosis of tuberculosis. *Lancet* 2000; 356:1099-1104.

(54) HPA Tuberculosis Programme Board. Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for tuberculosis (TB). 2008. London, Health Protection Agency UK.

(55) Barnes PF. Weighing gold or counting spots: which is more sensitive to diagnose latent tuberculosis infection? *American Journal of Respiratory and Critical Care Medicine* 2006; 174(7):731-732.

(56) Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB test for diagnosing latent *Mycobacterium tuberculosis* infection. *Morbidity and Mortality Weekly Report* 2003; 52(RR-2):15-18.

(57) Centers for Disease Control and Prevention. Guidelines for using the QuanitFERON-TB test for detecting *Mycobacterium tuberculosis* infection, United States. *Morbidity and Mortality Weekly Report* 2005; 54 (RR15)(December 16):49-55.

(58) Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. *Lancet Infect Dis* 2007; 7(6):428-438.

(59) Lalvani A. Diagnosing tuberculosis infection in the 21st century:new tools to tackle an old enemy. *Chest* 2007; 131(6):1898-1906.

(60) Public Health Agency of Canada. An Advisory Committee Statement by the Canadian Tuberculosis Committee on Updated Recommendations on interferon gamma release assays for latent tuberculosis infection. *Canada Communicable Disease Report* 2008; 34(October 2008):1-13.

(61) Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent TB infection; areas of uncertainty and recommendations for research. *Annals of Internal Medicine* 2007; 146(5):340-354.

(62) Johnson PD, Stuart RL, Grayson ML, Olden D, Clancy A, Ravn P et al. Tuberculin-purified protein deriviative-,MPT-64-,and ESAT-6 -stimulated gamma interferon responses in medical students before and after *Mycobacterium bovis* BCG vaccination and in patients with tuberculosis. *Clinical & Diagnostic Laboratory Immunology* 1999; 6(6):934-937.

(63) Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent TB infection in an intermediate-burden country. *Journal of the American Medical Association* 2005; 293(22):2756-2761.

(64) Nienhaus A, Loddenkemper R, Hauer B, Wolf N, Diel R. Latent TB infection in healthcare workers-evaluation of an interferon-gamma release assay. *Pneumologie* 2007; 61(4):219-223.

(65) Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole-blood IFN-{gamma} assay for the development of active TB disease. *Am J Respir Crit Care Med* 2008; 177(10):1164-1170.

(66) Leyten EM, Prins C, Bossink AW, Thijsen S, Ottenhoff TH, van Dissel J et al. Effect of tuberculin skin testing on Mycobacterium tuberculosis-specific interferon-gamma assay. *Eur Respir J* 2007; 29(6):1212-1216.

(67) Richeldi L, Ewer K, Losi M, Roversi P, Fabbri LM, Lalvani A. Repeated tuberculin testing does not induce false positive ELISPOT results. *Thorax* 2006; 61(2):180.

(68) Igari H, Watanabe A, Sato T. Booster phenomenon of QuantiFeron-TB Gold after prior intradermal PPD injection. *Int J Tuberc Lung Dis* 2007; 11(7):788-791.

(69) Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin testing. *Eur Respir J* 2007; 29(6):1282-1283.

(70) Palmer MV, Waters WR, Thacker TC, Greenwald R, Esfandiari J, Lyashchenko KP. Effects of different tuberculin skin-testing regimens on gamma interferon and antibody responses in cattle experimentally infected with *Mycobacterium Bovis*. *Clin Vaccine Immunol* 2006; 13(3):387-394.

(71) Lyashchenko K, Whelan AO, Greenwald R, Pollock JM, Anderson P, Hewinson RG et al. Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with *Mycobacterium Bovis* BCG and infected with *M. Bovis*. *Infect Immun* 2004; 72(5):2462-2467.

(72) Ferrand RA, Bothamley GH, Whelan A, Dockrell HM. Interferon-gamma responses to ESAT-6 in tuberculosis early into and after anti-tuberculosis treatment. *Int J Tuberc Lung Dis* 2005; 9(9):1034-1039.

(73) Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah D, Lugos MD et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. *BMC Infectious Diseases* 2006; 6:66.

(74) Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G et al. Effect of treatment of latent tuberculosis infection on the T cell response to *Mycobacterium tuberculosis* antigens. *J Infect Dis* 2006; 193(3):354-359.

(75) HPA Tuberculosis Programme Board. Health Protection Agency Position Statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis. Draft Interim HPA guidance. 2007. London. Available at http://www.hpa.org.uk.

(76) Meyer M, Clarke P, O Regan A. Utility of the lateral chest radiograph in the evaluation of patients with a positive tuberculin skin test result. *Chest* 2003; 124:1824-1827.

(77) Bureau of Tuberculosis Control NYC. Clinical policies and protocols. 4th edition. 2008. New York, USA, Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene.

(78) Paul EA, Lebowitz SM, Moore RE, Hoven CW, Bennet BA, Chen A. Nemesis revisited: tuberculosis infection in a New York City men's shelter. *American Journal of Public Health* 1993; 83(12):1743-1745.

(79) Zolopa AR, Hahn JA, Gorter R, Miranda J, Wlodarczyk D, Petersen J et al. HIV and tuberculosis infection in San Francisco's homeless adults. *Journal of the American Medical Association* 1994; 272(6):445-461.

(80) Ali S, Chew N, Manning P, Noonan N, Keane J, Bergin C. The prevalence of latent pulmonary tuberculosis (LTB) in a normal and high risk population group. *Chest* 2005; 128(4 (Suppl)):3978.

(81) Ferebee SH, Mount FW, Anastasiades AA. Prophylactic effects of INH on primary tuberculosis in children. *Am Rev TB Pulm Dis* 1957; 76:942-963.

(82) Watkins R, Brennan R, Plant A. Tuberculin reactivity and the risk of tuberculosis: a review. *Int J Tuberc Lung Dis* 2000; 4(10):895-903.

(83) Wilcke J, Poulson S, Askgaard D, et al. Tuberculosis in a cohort of Vietnamese refugees after arrival in Denmark 1979-82. *Int J Tuberc Lung Dis* 1998; 2(3):219-224.

(84) MacIntyre C, Plant A. Longitudional incidence of tuberculosis in South-East Asian refugees after re-settlement. *Int J Tuberc Lung Dis* 1999; 3(4):287-293.

(85) Antonucci G, Girardi E, Raviglione M, et al for the GISTA. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. *Journal of American Medical Association* 1995; 274(2):143-148.

(86) Miller RA, Lanza LA, Kline JN, et al. *Mycobacterium tuberculosis* in lung transplant recipients. *Am J Respir Crit Care Med* 1995; 152(1):374-376.

(87) Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. *Am J Respir Crit Care Med* 1994; 150:1460-1462.

(88) Malhotra KK, Parashar MK, Sharma RK, et al. Tuberculosis in maintenance haemodialysis patients. Study from an endemic area. *Postgrad Med J* 1981; 57(670):492-498.

(89) Rieder HL, Cauthen GM, Comstock GW, et al. Epidemiology of tuberculosis in the United States. *Epidemiol Rev* 1989; 11:79-98.

(90) Sutherland I. The evolution of clinical tuberculosis in adolescents. *Tubercle* 1966; 47:308.

(91) Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: A five-year surveillance study. *Am Rev Respir Dis* 1988; 137:805-809.

(92) Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors and the risk of tuberculosis. *Arthritis Rheum* 2006; 55(1):19-26.

(93) Keane J, Gershon AS, Wise R, Mirabile-Levens E, Kasznica J, Schwieterman WD. Tuberculosis associated with Infliximab, a Tumour Necrosis Factor {alpha}-Neutralising Agent. *New England Journal of Medicine* 2001; 345(15):1098-1104.

(94) Kim SJ, Hong YP, Lew WJ, et al. Incidence of pulmonary tuberculosis among diabetics. *Tuberc Lung Dis* 1995; 76(6):529-533.

(95) Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. *Am J Epidemiology* 1975; 101:263-382.

(96) Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. *Am J Epidemiology* 1974; 99(2):131-137.

(97) Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. *Int J Tuberc Lung Dis* 2002; 6(11):942-951.

(98) Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. Longitudional studies on the risk of tuberculosis in the general population of a low prevalence area. *Bull World Health Organ* 1969; 41:95-113.

(99) Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the US Navy: its distribution and decline. *Am Rev Respir Dis* 1974; 110:572-580.

(100) Cohn DL, El-Sadr WM. Treatment of latent TB infection. In: Reichmann LB, Hershfield ES, editors. Tuberculosis: A comprehensive international approach. Third ed. New York : Informa Healthcare USA; 2006.

(101) Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. *Cochrane Database of Systematic Reviews* 1999; (Issue 1).

(102) International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. *Bulletin of the World Health Organization* 1982; 60:555-564.

(103) Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? *International Journal of Tuberculosis and Lung Disease* 1999; 3(10):847-850.

(104) Centers for Disease Control and Prevention. Slide Sets:Epidemiology of Pediatric Tuberculosis in the United States, 1993-2006. Centers for Disease Control and Prevention USA . 2007.

(105) Paediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. *Pediatrics* 2004; 114:1175-1201.

(106) O Brien RJ, Long MW, Cross FS, Lyle MA, Snider DE. Hepatoxicity from isoniazid and rifampicin among children treated for tuberculosis. *Pediatrics* 1983; 72(4):491-499.

(107) World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. 2008. Geneva, World Health Organization.

(108) American Thoracic Society. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. *Am J Respir Crit Care Med* 2006; 174:935-952.

(109) American Academy of Pediatrics. Tuberculosis. In: Pickering LK, Baker CJ, Long SS, McMillan JA, editors. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.

(110) American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. *American Journal of Critical Care Medicine* 2000; 161:1376-1395.

(111) Barnes PF, Cave MD. Molecular epidemiology of tuberculosis. *New England Journal of Medicine* 2003; 349(12):1149-1156.

(112) Drobniewski FA, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. *The Lancet Infectious Diseases* 2003; 3:141-147.

(113) Department of Health. Report of the Working Party on Tuberculosis. 1996.

(114) Centers for Disease Control and Prevention. Proposed guidelines for goals for working safely with *Mycobacterium tuberculosis* in clinical, public health, and research laboratories. 1997. USA, Centers for Disease Control and Prevention. Available at http://www.cdc.gov/od/ohs/tb/tbdoc2.htm.

(115) Sommers HM, McClatchy JK. Laboratory diagnosis of the mycobacterioses. 1983.

(116) Tokars JI, Rudnick JR, Kroc K, Manangan L, Pugliese G, Huebner RE et al. US hospital mycobacteriology laboratories: status and comparison with state public health department laboratories. *Journal of Clinical Microbiology* 1996; 34(3):680-685.

(117) American Thoracic Society. Diagnostic standards and classification of tuberculosis. *American Review of Respiratory Disease* 1990; 142:725-735.

(118) Tenover FC, Crawford JT, Huebner RE, Geiter LJ, Horsburgh CR, Good RC. The resurgence of tuberculosis: is your laboratory ready? *Journal of Clinical Microbiology* 1993; 31(4):767-770.

(119) Huebner RE, Good RC, Tokars JI. Current practices in mycobacteriology: results of a survey of state public health laboratories. *Journal of Clinical Microbiology* 1993; 31(4):771-775.

(120) The Association of State and Territorial Public Health Laboratory Directors, Public Health Practice Program Office Division of Laboratory Systems Centers for Disease Control. *Mycobacterium tuberculosis*: assessing your laboratory. 1995.

(121) Styrt BA, Shinnick TM, Ridderhof JC, Crawford JT, Tenover FC. Turnaround times for mycobacterial cultures. *Journal of Clinical Microbiology* 1997; 35(4):1041-1042.

(122) Kaufman SHE, Hahn H. Mycobacteria and TB. Basel, Switzerland: Karger; 2003.

(123) Schlossberg D. Tuberculosis. Clinical Topics in Infectious Disease. Second edition ed. Springer-Verlag; 1988.

(124) Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of Clinical Microbiology. 9th ed. American Society for Microbiology; 2007.

(125) Kusznierz GF, Latini OA, Sequeira MD. Quality assessment of smear microscopy for acid-fast bacilli in the Argentine tuberculosis laboratory network,1983-2001. *International Journal of Tuberculosis and Lung Disease* 2004; 8(10):1234-1241.

(126) Health Protection Agency. Investigation of specimens for *Mycobacterium* species. National Standard Method BSOP 40 Issue 1. 1-28. 2006.

(127) Collins CH, Grange JM, Yates MD. Tuberculosis mycobacteriology. Organization and practice. 2nd ed. Oxford: Reed Educational and Professional Publishing Ltd; 1997.

(128) American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America. Treatment of tuberculosis. *Am J Respir Crit Care Med* 2003; 167:603-662.

(129) Centers for Disease Control and Prevention. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health care facilities. *Morbidity and Mortality Weekly Report* 1994; 43(RR-13):1-132.

(130) Vidal R, Juan A, Miravitlles M, Martin-Casabona N, Falgueras T. Incidence and significance of acid-fast bacilli in sputum smears at the end of anti-tuberculous treatment. *Chest* 1996; 109:1562-1565.

(131) Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. *Chest* 1999; 116:726-731.

(132) Conde MB, Soares SLM, Mello FCQ, Almeida LL, Reingold AL, Daley CL et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis. *American Journal of Critical Care Medicine* 2000; 162:2238-2240.

(133) McWilliams T, Wells AU, Harrison AC, Lindstrom S, Cameron RJ, Foskin E. Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis. *Thorax* 2002; 57:1010-1014.

(134) Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. *Clinical Infectious Diseases* 2007; 44:1415-1420.

(135) Zar HJ, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. *The Lancet* 2005; 365 (January 8th-14th):9454.

(136) Khan EA, Starke JR. Diagnosis of tuberculosis in children: increased need for better methods. *Emerging Infectious Diseases* 1995; 1(4):115-123.

(137) Pomputius W, Rost P, Dennehy H, Carter EJ. Standardisation of gastric aspirate technique improves yield in the diagnosis of tuberculosis in children. *Pediatric Infectious Disease Journal* 1997; 16:222-226.

(138) Thwaites GE, Hing Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculosis meningitis. *Journal of Clinical Microbiology* 2004; 42(1):378-379.

(139) Bouza E, Martin-Scapa C, Bernaldo de Quiros JC, Martinez-Hernandez D, Menarguez J, Gomez-Rodrigo J et al. High prevalence of tuberculosis in AIDS patients in Spain. *European Journal of Clinical Microbiology of Infectious Disease* 1988; 7(6):7875-7878.

(140) Kilby JM, Marques MB, Jaye DL, Tabereaux PB, Reddy VB, Waites KB. The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections. *American Journal of Medicine* 1998; 104(2):123-128.

(141) Villegas MV, Labrada LA, Saravia NG. Evaluation of polymerase chain reaction, adenosine deaminase and interferon-gamma in pleural fluid for the differential diagnosis of pleural tuberculosis. *Chest* 2000; 118:1355-1364.

(142) Mitarai S, Shishido MS, Kurashima A, Tamura A, Nagai H. Comparative study of amplicor Mycobacterium PCR and conventional methods for the diagnosis of pleuritis caused by mycobacterial infection. *International Journal of Tuberculosis and Lung Disease* 2000; 4(9):871-876.

(143) Centers for Disease Control and Prevention. Use of fluorochrome staining for detecting acid-fast mycobacteria. 2004. Atlanta USA, Centers for Disease Control and Prevention.

(144) Lipsky BA, Gates J, Tenover FC, Plorde JJ. Factors affecting the clinical value of microscopy for acid-fast bacilli. *Review of Infectious Diseases* 1984; 6(2):214-222.

(145) Somoskovi A, Hotaling JE, Fitzgerald M, O'Donnell D, Parson LM, Salfinger M. Lessons from a proficiency testing event for acid-fast bacilli. *Chest* 2001; 120:250-257.

(146) Wright PW, Wallace RJ, Wright NW, Brown BA, Griffith DE. Sensitivity of fluorochrome microscopy for detection of *Mycobacterium tuberculosis* versus nontuberculous mycobacteria. *Journal of Clinical Microbiology* 1998; 36(4):1046-1049.

(147) World Health Organization. Laboratory services in tuberculosis control. Organization and managment Part 1. WHO/TB/98.258. 1998. World Health Organization.

(148) Steingart KR, Henry M, Ng V, Hopewell PC, Ramsay A, Cunningham J et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. *The Lancet* 2006; 6:570-581.

(149) Murray SJ, Barrett A, Magee JG, Freeman R. Optimisation of acid fast smears for the direct detection of mycobacteria in clinical samples. *Journal of Clinical Pathology* 2003; 56:613-615.

(150) Whittier S, Olivier K, Gilligan P, Knowles M, Della-Latta P. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of non-tuberculous mycobacteria in sputum samples from cystic fibrosis patients. The non-tuberculous mycobacteria in cystic fibrosis study group. *Journal of Clinical Microbiology* 1997; 35:2706-2708.

(151) Bange FC, Bottger EC. Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis. *European Journal of Clinical Microbiology of Infectious Disease* 2002; 21 (7):546-548.

(152) Tortoli E, Cichero P, Chirillo MG, Gismondo MR, Bobo L, Gesu G et al. Multicenter comparison of ESP culture system II with BACTEC 460TB and Lowenstein-Jensen medium for recovery of mycobacteria from different clinical specimens, including blood. *Journal of Clinical Microbiology* 1998; 36(5):1378-1381.

(153) Benjamin WH, Waites KB, Beverly A, Gibbs L, Waller M, Nix S et al. Comparison of the MB/BacT system with a revised antibiotic supplement kit to the BACTEC 460 system for detection of mycobacteria in clinical specimens. *Journal of Clinical Microbiology* 1998; 36(11):3234-3238.

(154) Freeman R, Magee J. Continuous automates mycobacterial liquid culture (CAMLiC) systems. *PHLS Microbiology Digest* 1997; 14(2):67-71.

(155) Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. *Journal of Clinical Microbiology* 2004; 42(5):2321-2325.

(156) Pfyffer GE, Welscher HM, Kissling P, Cieslak C, Casal MJ, Gutierrez J et al. Comparison of the mycobacteria growth indicator tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. *Journal of Clinical Microbiology* 1997; 35(2):364-368.

(157) Roggenkamp A, Hornef MW, Masch A, Aigner B, Autenrieth IB, Heesemann J. Comparison of MB/BacT and BACTEC 460 TB systems for recovery of mycobacteria in a routine diagnostic laboratory. *Journal of Clinical Microbiology* 1999; 37(11):3711-3721.

(158) Centers for Disease Control and Prevention. Updated guidelines for the use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. *Morbidity and Mortality Weekly Report* 2009; 58(1):7-10.

(159) Noordhoek GT, Kolk AHJ, Bjune G, Catty D, Dale JW, Fine PEM et al. Sensitivity and specificity of PCR for detection of *Mycobacterium tuberculosis*: a blind comparison study among seven laboratories. *Journal of Clinical Microbiology* 1994; 32(2):277-284.

(160) Noordhoek GT, Van Embden JDA, Kolk AHJ. Reliability of nucleic acid amplification for detection of *Mycobacterium tuberculosis*: an international collaborative quality control study among 30 laboratories. *Journal of Clinical Microbiology* 1996; 34(10):2522-2525.

(161) Sarmiento OL, Weigle KA, Alexander J, WEber DJ, Miller WC. Assessment by meta-analysis of PCR for diagnosis of smear-negative pulmonary tuberculosis. *Journal of Clinical Microbiology* 2003; 41(7):3233-3240.

(162) American Thoracic Society Workshop. Rapid diagnostic tests for tuberculosis. What is the appropriate use? *American Journal of Critical Care Medicine* 1997; 155:1804-1814.

(163) Ridderhof JC, Williams LO, Legois S, Shult PA, Metchock B, Kubista LN et al. Assessment of laboratory performance of nucleic acid amplification tests for detection of *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* 2003; 41(11):5258-5261.

(164) Telenti A, Marchesi F, Balz M, Bally F, Bottger EC, Bodmer T. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. *Journal of Clinical Microbiology* 1993; 31(2):175-178.

(165) Padilla E, Gonzalez V, Manterola JM, Perez A, Quesada MD, Gordillo S et al. Comparative evaluation of the new version of the INNO-LiPA mycobacteria and GenoType Mycobacterium

assays for identification of *Mycobacterium* species from MB/BacT cultures artificially inoculated with mycobacterial strains. *Journal of Clinical Microbiology* 2004; 42(7):3083-3088.

(166) Niemann S, Rusch-Gerdes S, Joloba ML, Whalen CC, Guwatudde D, Ellner JJ et al. *Mycobacterium africanum* subtype II is associated with two distinct genotypes and is a major cause of human tuberculosis in Kampala, Uganda. *Journal of Clinical Microbiology* 2002; 40(9):3398-3405.

(167) Seng Goh K, Legrand E, Sola C, Rastogi N. Rapid differentiation of "*Mycobacterium canetti*" from other *Mycobacterium tuberculosis* complex organisms by PCR-restriction analysis of the hsp65 gene. *Journal of Clinical Microbiology* 2001; 39(10):3705-3708.

(168) Gutierrez MC, Samper S, Jimenez MS, van Embden JDA, Garcia Martin JF, Martin C. Identification by spoligotyping of a caprine genotype in *Mycobacterium bovis* strains causing human tuberculosis. *Journal of Clinical Microbiology* 1997; 35(12):3328-3330.

(169) Kubica T, Rusch-Gerdes S, Niemann S. *Mycobacterium bovis* subsp. *caprae* caused one-third of human *M. bovis*-associated tuberculosis cases reported in Germany between 1999 and 2001. *Journal of Clinical Microbiology* 2003; 41(7):3070-3077.

(170) van Soolingen D, van der Zanden AGM, de Haas PEW, Noordhoek GT, Kiers A, Foudraine NA et al. Diagnosis of *Mycobacterium microti* infections among humans by using novel genetic markers. *Journal of Clinical Microbiology* 1998; 36(7):1840-1845.

(171) Cousins DV, Bastida R, Cataldi A, Quse V, Redrobe S, Dow S et al. Tuberculosis in seals caused by a novel member of the *Mycobacterium tuberculosis* complex: *Mycobacterium pinnipedii* sp. *nov*. *International Journal of Systematic and Evolutionary Microbiology* 2003; 53:1305-1314.

(172) Richter E, Weiznegger M, Rusch-Gerdes S, Niemann S. Evaluation of genotype MTBC assay for differentiation of clinical *Mycobacterium tuberculosis* complex isolates. *Journal of Clinical Microbiology* 2003; 41(6):2672-2675.

(173) Richter E, Weiznegger M, Fahr AM, Rusch-Gerdes S. Usefulness of the GenoType MTBC assay for differentiating species of the *Mycobacterium tuberculosis* complex in cultures obtained from clinical specimens. *Journal of Clinical Microbiology* 2004; 42(9):4303-4306.

(174) Mostowy S, Onipede A, Gagneux S, Niemann S, Kremer K, Desmond EP et al. Genomic analysis distinguishes *Mycobacterium africanum*. *Journal of Clinical Microbiology* 2004; 42(8):3594-3599.

(175) Woods GL, Brown-Elliott BA, Desmond EP, Hall GS, Heifets L, Pfyffer GE et al. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. NCCLS document M24-A. 2003. Pennsylvania, US.

(176) Makinen J, Marttila HJ, Marjamaki M, Viljanen MK, Soini H. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* 2006; February :350-352.

(177) van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B et al. Strain identification of *Mycobacterium tuberculosis* by DNA fingerprinting: recommendations for standardised methodology. *Journal of Clinical Microbiology* 1993; 31:406-409.

(178) Supply P, Allix CA, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* 2006; 44(12):4498-4510.

(179) Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S et al. Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *Journal of Clinical Microbiology* 1997; 35:907-914.

(180) Centers for Disease Control and Prevention. Notice to readers: new CDC program for rapid genotyping of *Mycobacterium tuberculosis* isolates. *Morbidity and Mortality Weekly Report* 2005; 54(02):47.

(181) Burman WJ, Reves RR. Review of false-positive cultures for *Mycobacterium tuberculosis* and recommendations for avoiding unnecessary treatment. *Clinical Infectious Diseases* 2000; 31:1390-1395.

(182) Breese PE, Burman WJ, Hildred M, Stone B, Wilson ML, Yang Z et al. The effect of changes in laboratory practices on the rate of false positive cultures of *Mycobacterium tuberculosis. Archives of Pathology and Laboratory Medicine* 2001; 125(9):1213-1216.

(183) Gascoyne-Binzi DM, Barlow REL, Frothingham R, Robinson G, Collyns TA, Gelletlie R et al. Rapid identification of laboratory contamination with *Mycobacterium tuberculosis* using variable number tandem repeat analysis. *Journal of Clinical Microbiology* 2001; 39(1):69-74.

(184) Small PM, McClenny NB, Singh SP, Schoolnik GK, Tompkins LS, Mickelsen PA. Molecular strain typing of *Mycobacterium tuberculosis* to confirm cross-contamination in the mycobacteriology laboratory and modification to procedures to minimize occurrence of false-positive cultures. *Journal of Clinical Microbiology* 1993; 31(7):1677-1682.

(185) Carroll NM, Richardson M, van Helden PD. Criteria for identification of cross-contamination of cultures of *Mycobacterium tuberculosis* in routine microbiology laboratories. *Journal of Clinical Microbiology* 2003; 41(5):2269-2270.

(186) Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P et al. Comparison of T-cell based assay with tuberculin skin test for diagnosis of *Mycobacterium tuberculosis* infection in a school tuberculosis outbreak. *Lancet* 2003; 361(9364):1168-1173.

(187) Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G et al. Direct ex vivo analysis of antigen specific IFN-secreting CD4 T cells in *Mycobacterium tuberculosis* infected individuals: associations with clinical disease state and effect of treatment. *Journal of immunology* 2001; 167:5217-5225.

(188) Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ et al. Enhanced contact tracing and spatial tracking of *Mycobacterium tuberculosis* infection by enumeration of antigen-specific T-cells. *The Lancet* 2001; 357:2017-2021.

(189) Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Larif M, Conlon CP et al. Rapid detection of *M. tuberculosis* infection by enumeration of antigen-specific cells. *American Journal of Critical Care Medicine* 2001; 163(4):824-828.

(190) Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS et al. Enumeration of T-cells specific for RD1-encoded antigens suggests a high prevalence of latent *Mycobacterium tuberculosis* infection in healthy urban Indians. *Journal of Infectious Disease* 2001; 183:469-477.

(191) Holden M, Dubin RD, Diamond PH. Frequency of negative intermediate strength tuberculin sensitivity in patients with active tuberculosis. *New England Journal of Medicine* 1971; 285:1506-1509.

(192) Battershill JH. Cutaneous testing in the elderly patient with tuberculosis. *Chest* 1980; 77:188-189.

(193) Howard WL, Klopfenstein MD, Steininger WJ, Woodruff CE. The loss of tuberculin sensitivity in certain patients with active pulmonary tuberculosis. *Chest* 1970; 57:530-534.

(194) Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM et al. Comparison of two commercial interferon-gamma assays for diagnosing *Mycobacterium tuberculosis* infection. *European Respiratory Journal* 2006; 28:24-30.

(195) Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with *Mycobacterium tuberculosis*: a prospective study. *The Lancet* 2006; 367:1328-1334.

(196) Goletti D, Carrara S, Vincenti D, Saltini C, Rizzi EB, Schinina V et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. *Clinical Microbiology and Infection* 2006; 12:544-550.

(197) Harada N, Nakajima Y, Higuchi K, Sekiya Y, Rothel J, Mori T. Screening for tuberculosis infection using whole-blood interferon-gamma and Mantoux testing among Japanese healthcare workers. *Infection Control and Hospital Epidemiology* 2006; 27(5):442-448.

(198) Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T. Tuberculosis contact investigation with a new specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. *Respiratory Research* 2006; 7:77.

(199) Health and Safety Commission's Advisory Committee on Dangerous Pathogens. Categorisation of biological agents according to hazard and categories of containment. 1995. London, Health and Safety Executive.

(200) Health and Safety Commission's Advisory Committee on Dangerous Pathogens. The management, design and operation of microbiological containment laboratories. London: 2001.

(201) Health and Safety Executive Advisory. Safe working and the prevention of infection in clinical laboratories and similar facilities. London: HSE Books; 2003.

(202) Health and Safety Executive Advisory Committee on Dangerous Pathogens. Biological agents: managing the risks in laboratories and healthcare premises. London: HSE Books; 2005.

(203) Centers for Disease Control and Prevention, National Institutes of Health. Biosafety in microbiology and biomedical laboratories. 1999.

(204) Government Publications TSOD. Carriage of Dangerous Goods by Road Regulations 2007 (S.I.: No 288/2007). 2007.

(205) European Union. European Agreement concerning the International Carriage of Dangerous Goods by Road (ADR) 2007. Geneva: United Nations Publications; 2007.

(206) Almagro M, Del Pozo J, Rodriguez-Lozano J, Silva JG, Yebra-Pimentel MT, Fonseca E. Metastatic tuberculous abcesses in an immunocompetent patient. *Clinical Experimental Dermatology* 2005; 30(3):247-249.

(207) Iype EM, Ramdas K, Pandey M, Jayasaree K, Sebastian P, Nair MK. Primary tuberculosis of the tongue: report of three cases. *British Journal of Oral and Maxillofacial Surgery* 2001; 39(5):402-403.

(208) Khokkanen VM, Iagafarova RK. Clinical and epidemiological characteristics of patients with eye tuberculosis. *Problemy Tuberkuleza* 1998; 6:14-15.

(209) Lamba H, Byrne M, Goldin R, Jenkins C. Tuberculosis of the cervix, case presentation and a review of the literature. *Sexually Transmitted Infections* 2002; 78:62-63.

(210) Drancourt M, Carrieri P, Gevaudan MJ, Raoult D. Blood agar and *Mycobacterium tuberculosis*: the end of a dogma. *Journal of Clinical Microbiology* 2003; 41(4):1710-1711.

(211) Public Health Laboratory Service. Safety Precautions. 1993. London, The Blackmore Press.

(212) Zwadyk P, Down JAJr, Myers N, Dey MS. Rendering of mycobacteria safe for molecular diagnostic studies and development of lysis method for strand displacement amplification and PCR. *Journal of Clinical Microbiology* 1994; 32:2140-2146.

(213) Doig C, Seagar AL, Watt B, Forbes KJ. The efficacy of the heat killing of *mycobacterium tuberculosis. Journal of Clinical Pathology* 2002; 55:778-779.

(214) Blackwood KS, Burdz TV, Turenne CY, Sharma MK, Kabani AM, Wolfe JN. Viability testing of material derived from *Mycobacterium tuberculosis* prior to removal from a Containment Level-III Laboratory as part of a laboratory risk assessment program. *BMC Infectious Diseases* 2005; 5:4.

(215) Centers for Disease Control and Prevention. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC and the Infectious Diseases Society of America. *Morbidity and Mortality Weekly Report* 2005; 54(No. RR-12):1-81.

(216) Pirkis JE, Speed BR, Yung AP, Dunt DR, MacIntyre CR, Plant AJ. Time to initiation of anti-tuberculosis treatment. *International Journal of Tuberculosis and Lung Disease* 1996; 77(5):401-406.

(217) World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2006. Geneva, World Health Organization.

(218) Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary TB in HIV-negative patients: a randomized clinical trial. *Lancet* 2002; 360:28-34.

(219) Blumberg MH, Leonard MK, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. *Journal of American Medical Association* 2005; 293:2776-2784.

(220) Figueroa-Damian R, Arredondo-Garcia JL. Pregnancy and tuberculosis:influence of treatment on perinatal outcome. *Am J Perinatol* 1998; 15:303-306.

(221) Snider DE, Layde RM, Johnson MW, et al. Treatment of tuberculosis during pregnancy. *Am Rev Respir Dis* 1980; 122:65-79.

(222) Addington WW. Patient compliance:the most serious remaining problem in the control of tuberculosis in the United States. *Chest* 1979; 76 (suppl):741-743.

(223) Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. *N Engl J Med* 1994; 330:1179-1184.

(224) Ormerod LP, Horsfield N, Green RM. Tuberculosis treatment outcome monitoring:Blackburn 1988-2000. *Int J Tuberc Lung Dis* 2002; 6:662-665.

(225) Government of Ireland. Health Act. Available at www.irishstatutebook.ie/front.html. 1947.

(226) Government of Ireland. Health Act. Available at www.irishstatutebook.ie/front.html. 1953.

(227) Hutton MD, Stead WW, Cauthen GM, Bloch AB, Ewing WM. Nosocomial transmission of tuberculosis associated with a draining abcess. *Journal of Infectious Diseases* 1990; 161(2):286-295.

(228) Centers for Disease Control and Prevention. Core Curriculum on TB : What the clinician should know (2000, 4th edition). 2000. Atlanta, USA, Centers for Disease Control.

(229) Centers for Disease Control and Prevention. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *Morbidity and Mortality Weekly Report* 2005; 54(No. RR-17):1-141.

(230) Siegel JD, Rhinehart E, Jackson M, Chiarello L, and the Healthcare Institution Control Practices Advisory Committee. Guidelines for Isolation Precautions:Preventing transmission of infectious agents in healthcare settings, 2007. 2007. Atlanta, USA, Centers for Disease Control and Prevention.

(231) Department of Health UK/NHS Estates. HBN 4: In patient accommodation: options for choice - Supplement 1. Isolation facilities in acute settings. 2005. Department of Health UK.

(232) Menzies D, Fanning A, Yuan L, Fitzgerald JM. Hospital ventilation and risk for tuberculosis infection in Canadian healthcare workers. *Ann Intern Med* 2000; 133:779-789.

(233) American Institute of Architects. Guidelines for design and construction of hospital and healthcare. 1-33. 1996. Washington, USA, American Institute of Architects.

(234) Department of Health. The prevention and control of tuberculosis in the United Kingdom: UK guidance on the prevention and control of transmission of 1. HIV-related tuberculosis 2. drug-resistant, including multiple drug-resistant, tuberculosis. 1-94. 1998. London, Department of Health.

(235) Walker JT, Hoffman P, Bennet AM, Vos MC, Thomas M, Tomlinson N. Hospital and community acquired infection and the built environment-design and testing of infection control rooms. *Journal of Hospital Infection* 2007; 65(S2):43-49.

(236) Strategy for the control of Antimicrobial Resistance in Ireland (SARI). Infection Prevention and Control Building Guidelines for Acute Hospitals in Ireland. 2008. Dublin, HSE Health Protection Surveillance Centre.

(237) Cunney R, Humphreys H, Murphy N. Survey of acute hospital infection control resources and services in the Republic of Ireland. *Journal of Hospital Infection* 2006; 64(1):63-68.

(238) Collins CH, Grange JM. Tuberculosis acquired in laboratories and necropsy rooms. *Commun Dis Public Health* 1999; 2:161-167.

(239) The Royal College of Pathologists. Guidelines on autopsy practice:report of a working group of The Royal College of Pathologists. 2002. London, The Royal College of Pathologists.

(240) Government Publications TSOD. Guidelines to the Safety, Health and Welfare at Work (Chemical Agents) Regulations (S.I.: No. 619 of 2001). 2001.

(241) Health Protection Scotland. Tuberculosis:Clinical diagnosis and management of tuberculosis and measures for its prevention and control in Scotland. Health Protection Network Scottish Guidance 5. 2009. Glasgow, Health Protection Scotland.

(242) Fine PEM, Rodrigues LC. Mycobacterial diseases modern vaccines: Lancet review. *Lancet* 1990.

(243) Fine PEM. Bacille Calmette-Guerin vaccines: a rough guide. *Clinical Infectious Diseases* 1995; 20(4):982-991.

(244) Colditz GA, Berkey CS, Mosteller F. The efficacy of BCG vaccination in newborns and infants in the prevention of tuberculosis. Meta-analysis of the published data. *Paediatrics* 1995; 96:29-35.

(245) Fine PEM. Variation in the protection by BCG: implications of and for heterologous immunity. *Lancet* 1995; 346:1339-1345.

(246) World Health Organization. Expanded programme on immunisation. Immunisation schedules in the WHO European Region 1995. *Weekly Epidemiological Record* 1995; 70:221-228.

(247) Tala E, Romanus V, Tala-Heikkila M. Bacille Camille-Guerin vaccination in the 21st century. *European Respiratory Monthly* 1997; 4:2362-2369.

(248) Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of TB: meta-analysis of the published literature. *Journal of the American Medical Association* 1994; 271:698-702.

(249) Sutherland I. Effectiveness of BCG vaccination in England and Wales in 1983. *Tubercle* 1987; 68(2):81-92.

(250) Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life: final report to the Medical Research Council. *British Medical Journal* 1977; 6(6082):293-295.

(251) Kritski AL, Marques MJO, Rabahi MF, et al. Transmission of tuberculosis in close contacts of patients with multi-drug resistant tuberculosis. *American Journal of Respiratory Critical Care Medicine* 1996; 153:331-335.

(252) International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using Bacille Camille Guerin (BCG) in countries with low prevalence of tuberculosis. *Tuberculous Lung Disease* 1994; 75:179-180.

(253) National Public Health Institute Finland. Evaluation of Finnish Newborn BCG Programme. 2001. Finland.

(254) National Advisory Committee on Immunisation. Statement on BCG. *Canada Communicable Disease Report* 2004; 30:1-12.

(255) National Immunisation Advisory Committee of the Royal College of Physicians of Ireland. Immunisation guidelines. 2007. Royal College of Physicians of Ireland, Dublin.

(256) Bothamley GH, Cooper E, Shingadia D, Mellanby A. Tuberculin testing before BCG vaccination. *British Medical Journal* 2003; 327:243-244.

(257) Department of Health UK. Tuberculosis. In: Salisbury D, Ramsey M, Noakes K, editors. Immunisation against infectious disease. Department of Health; 2006. 391-420.

(258) Benwell JB, Burman D. BCG vaccination after replacement blood transfusion. *British Medical Journal* 1957; 1(5010):105.

(259) Campbell WAB, Purser HM. BCG vaccination after replacement transfusion (Letter). *British Medical Journal* 1956; 2(5001):1115.

(260) D'Avignon M, Berglund G. BCG vaccination after replacement blood transfusion. *British Medical Journal* 1956; 2(5005):1363.

(261) Hutcheson AS, MacPherson P. BCG vaccination after blood replacement. *British Medical Journal* 1956; 2(4997):863-864.

(262) Health Protection Surveillance Centre. Report on the Epidemiology of TB in Ireland 2004. 2006. Dublin, Health Protection Surveillance Centre.

(263) Esmonde TF, Petheram IS. Audit of tuberculosis contact tracing procedures in south Gwent. *Respiratory Medicine* 1991; 85(5):-421.

(264) Hussain SF, Watura R, Cashman B, Campbell IA, Evans MR. Tuberculosis contact tracing: are the British Thoracic Society guidelines still appropriate? *Thorax* 1992; 47(11):984-985.

(265) Kumar S, Innes JA, Skinner C. Yield from tuberculosis contact tracing in Birmingham. *Thorax* 1992; 47:875.

(266) Ormerod LP. Tuberculosis contact tracing. Blackburn 1982-1990. *Respiratory Medicine* 2007; 87(2):127-131.

(267) Teale C, Cundall DB, Pearson SB. Time of development of tuberculosis in contacts. *Respiratory Medicine* 1991; 85(6):475-477.

(268) Irish C, Jolly E, Baker T. Contact tracing smear negative and non-pulmonary tuberculosis in a high incidence area. *Thorax* 1997; 52 (Suppl 6):a34.

(269) Hardinge FM, Black M, Chamberlain P. TB contact tracing in South Buckinghamshire from 1994 to mid 1998. *American Journal of Respiratory and Critical Care Medicine* 1999; 159 (Suppl):a303.

(270) Ansari S, Thomas S, Campbell IA, Furness L, Evans MR. Refined tuberculosis contact tracing in a low incidence area. *Respiratory Medicine* 1998; 92(9):1127-1131.

(271) Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle. *Tuberculous Lung Disease* 1992; 73:73-76.

(272) Menzies D, Tannenbaum TN, Fitzgerald JM. Tuberculosis:10. Prevention. *Canadian Medical Association Journal* 1999; 161(6):717-724.

(273) Riley RL, Mills CC, O'Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. *American Review of Respiratory Disease* 1962; 85:511-525.

(274) Braden CR. Infectiousness of a university student with laryngeal and cavitary tuberculosis. *Clinical Infectious Diseases* 1995; 21(565):570.

(275) Templeton G, Illing LA, Young L, Cave D, Stead WW, Bates JH. The risk of transmission of *Mycobacterium tuberculosis* at the bedside and during autopsy. *Annals of Internal Medicine* 1995; 122(922):925.

(276) Sterling TR, Pope DS, Bishai WR, Harrington S, Gershon RR, Chaisson RE. Transmission of *Mycobacterium tuberculosis* from a cadaver to an embalmer. *New England Journal of Medicine* 2000; 342:246-248.

(277) Lauzardo M, Lee P, Duncan H, Hale Y. Transmission of *Mycobacterium tuberculosis* to a funeral director during routine embalmer. *Chest* 2001; 119:640-642.

(278) Catanzaro A. Nosocomial tuberculosis. *American Review of Respiratory Disease* 1982; 125:559-562.

(279) World Health Organization. Report on the technical discussions at the twenty-first World Health Assembly on "National and Global Surveillance of Communicable Diseases". A21/Technical Discussions/5. 1968. Geneva, World Health Organization.

(280) Menzies D. Issues in the management of contacts of patients with active pulmonary tuberculosis. *Canadian Journal of Public Health* 1997; 88:197-201.

(281) Bailey WC, Gerald LB, Kimmerling ME, Redden D, Bruce F, Tang S et al. Predictive model to identify positive tuberculosis skin test results during contact investigations. *Journal of American Medical Association* 2002; 287:996-1002.

(282) Madhi F, Fuheman C, Monnet I, Atassi K, Poirier C, Housset B et al. Transmission of tuberculosis from adults to children in a Paris suburb. *Pediatric Pulmonology* 2002; 34(3):159-163.

(283) Lawrence RM. Tuberculosis in children. In: Rom WN, Garay SM, editors. Tuberculosis. Boston MA: Little, Brown & Company; 1996.

(284) Curtis AB, Ridzon R, Vogel R, McDonough S, Hargreaves J, Ferry J et al. Extensive transmission of *Mycobacterium tuberculosis* from a child. *New England Journal of Medicine* 1999; 341(20):1491-1495.

(285) Riley RL. *The J. Burns Amberson lecture: aerial dissemination of pulmonary tuberculosis. American Review of Tuberculous Pulmonary Disease* 1957; 50:90-106.

(286) Nardell EA. *Reducing the probability of nosocomial tuberculosis transmission in the AIDS era. American Review of Respiratory Disease* 1999; 142:501-503.

(287) Gryzbowski S, Barnett GD, Styblo K. *Contacts of cases of active pulmonary tuberculosis. Bulletin of the International Union Against Tuberculosis and Lung Disease* 1975; 50:90-106.

(288) Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. *American Journal of Respiratory and Critical Care Medicine* 2000; 162:2033-2038.

(289) Reichler MR, Reves R, Bur S, Mangura BT, Ford J, Valway SE et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. *Journal of American Medical Association* 2002;(287):991-995.

(290) Gerald LB, Tang S, Bruce F, Redden D, Kimmerling ME, Brook N et al. A decision tree for tuberculosis contact investigation. *American Journal of Respiratory and Critical Care Medicine* 2002; 166:1122-1127.

(291) Golub JE, Cronin WA, Obasanjo OO, Coggin W, Moore K, Pope DS et al. Transmission of *Mycobacterium tuberculosis* through casual contact with an infectious case. *Archives of Internal Medicine* 2001; 161(18):2254-2258.

(292) Centers for Disease Control and Prevention. Self-study modules on tuberculosis: contact investigations for tuberculosis. Atlanta, GA, US: Department of Health and Human Services, CDC; 1999.

(293) Bates JH, Potts WE, Lewis M. Epidemiology of primary tuberculosis in an industrial school. *New England Journal of Medicine* 1965; 272:714-717.

(294) Bock NN, Mallory JP, Mobley N, DeVoe B, Taylor BB. Outbreak of tuberculosis associated with a floating card game in the rural south: lessons for tuberculosis contact investigations. *Clinical Infectious Diseases* 1998; 27:1221-1226.

(295) Bleiker MA, Misljenovic O. The application of the WHO standard tuberculin test in the elimination phase of TB. *Bulletin of the International Union Against Tuberculosis and Lung Disease* 1990; 65:56.

(296) Public Health Agency of Canada. An advisory committee statement (ACS) by the Canadian Tuberculosis Committee on Interferon Gamma Release Assays for Latent TB Infection. *Canada Communicable Disease Report* 2007; 33(10):1-18.

(297) Menzies D. Tuberculin skin testing. In: Reichman LB, Hershfield ES, editors. Tuberculosis: a comprehensive international approach. New York: Informa Healthcare USA; 2006.

(298) The Scottish Office Department of Health. The control of tuberculosis in Scotland. 1998. Edinburgh, The Scottish Office Department of Health.

(299) Agata E-MC, Wise S, Stewart A, Lefkowitz LB Jr. Nosocomial transmission of *Mycobacterium tuberculosis* from an extrapulmonary site. *Infection Control and Hospital Epidemiology* 2001; 22(1):10-12.

(300) Drobniewski FA, Ferguson J, Barritt K, Higgins RM, Higgon M, Neave D et al. Follow up of an immunocompromised contact group of a case of open pulmonary tuberculosis on a renal unit. *Thorax* 1995; 50(8):863-868.

(301) Zaza S, Blumberg HM, Beck-Sague C, Haas WH, Woodley CL, Pineda M et al. Nosocomial transmission of *Mycobacterium tuberculosis*: role of health care workers in outbreak propagation. *Journal of Infectious Diseases* 1995; *172* (1542):1549.

(302) Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. *Thorax* 2000; 55:887-901.

(303) World Health Organization. Tuberculosis and air travel:Guidelines for prevention and control:Third Edition. 1-48. 2008. Geneva, World Health Organization.

(304) Driver CR, Valway SE, Morgan WM, Onorato IM, Castro KG. Transmission of *Mycobacterium tuberculosis* associated with air travel. *Journal of American Medical Association* 1994; 272(13):1031-1035.

(305) Kenyon TA, Valway SE, Ihle WW, Onorato IM, Castro KG. Transmission of multidrug-resistant *Mycobacterium tuberculosis* during a long airplane flight. *New England Journal of Medicine* 1996; 334(15):933-938.

(306) World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. 2006. Geneva, World Health Organization.

(307) World Health Organization. Prisons a "breeding ground for disease" International conference in Moscow to highlight the link between public health and prison health. Note to the press EURO 12/03. 20-10-2003. Copenhagen, Word Health Organization.

(308) Aerts A, Hauer B, Wanlin M, Veen J. Tuberculosis and tuberculosis control in European prisons. *International Journal of Tuberculosis and Lung Disease* 2006; 10:1215-1223.

(309) Centers for Disease Control and Prevention. Tuberculosis transmission in multiple correctional facilities - Kansas, 2002-2003. *Morbidity and Mortality Weekly Report* 2004; 53:734-738.

(310) Darbyshire JH. Tuberculosis in prisons. *British Medical Journal* 1989; 299(6704):874.

(311) Ruddy MC, Davies AP, Yates MD, Yates S, Balasegaram S, Drabu Y et al. Outbreak of isoniazid resistant tuberculosis in north London. *Thorax* 2004; 59(4):279-285.

(312) Centers for Disease Control and Prevention. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. *Morbidity and Mortality Weekly Report* 2006; 55(RR-9):1-53.

(313) Miller AC, Butler WR, McInnis B, Boutotte J, Etkind S, Sharnprapai S et al. Clonal relationships in a shelter-associated outbreak of drug-resistant tuberculosis: 1983-1997. *International Journal of Tuberculosis and Lung Disease* 2002; 6:872-878.

(314) Klovdahl AS, Graviss EA, Yaganehdoost A, Ross MW, Wanger A, Adams GJ et al. Networks and tuberculosis: an undetected community outbreak involving public places. *Social Science and Medicine* 2001; 52(5):681-694.

(315) Yaganehdoost A, Graviss EA, Ross MW, Adams GJ, Ramaswamy S, Wanger A et al. Complex transmission dynamics of clonally related virulent *Mycobacterium tuberculosis* associated with barhopping by predominantly human immunodeficiency virus-positive gay men. *Journal of Infectious Diseases* 1999; 180(4):1245-1251.

(316) Etkind S. Impact of genotyping of *Mycobacterium tuberculosis* on Public Health Practice in Massachusetts. (Tuberculosis Genotyping Network). *Emerging Infectious Diseases* 2002; 8(11):1285-1289.

(317) Canadian Lung Association/Health Canada. Canadian tuberculosis standards. 5th edition. 2000. Canadian Lung Association/Health Canada.

(318) Wilson JMG, Jungner G. *Principles and practice of screening for disease*. Geneva : World Health Organization; 1968.

(319) Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. *New England Journal of Medicine* 1995; 332:92-98.

(320) Aitken ML, Anderson KM, Albert RK. Is the tuberculin screening program of hospital employees still required? *American Review of Respiratory Disease* 1987; 136:805-807.

(321) Bailey TC, Fraser VJ, Spitznagel EL, Dunagan WC. Risk factors for a positive tuberculin test among employees of an urban midwestern teaching hospital. *Annals of Internal Medicine* 1995; 122:580-585.

(322) Menzies D, Pai M. Risk of tuberculosis infection and disease associated with work in health care settings. *International Journal of Tuberculosis and Lung Disease* 2007; 11(6):593-605.

(323) Hill A, Burge A, Skinner C. Tuberculosis in National Health Service hospital staff in the west Midlands region of England 1992-5. *Thorax* 1997; 52:994-997.

(324) Meredith S, Watson JM, Citron KM, Cockcroft A, Darbyshire JH. Are healthcare workers in England and Wales at increased risk of tuberculosis? *British Medical Journal* 1996; 313(7056):522-525.

(325) Anderson C, Abubakar I, Maguire H, Sonnenberg P. Survey of tuberculosis incidents in hospital healthcare workers, England and Wales, 2005. *Journal of Public Health* 2007; 29(3):292-297.

(326) Department of Health. Health clearance for tuberculosis: hepatitis B, hepatitis C and HIV: new healthcare workers. 2007. London.

(327) Panlilo AL, Burwen DR, Curtis AB, et al. Tuberculin skin testing surveillance of healthcare personnel. *Clin infect Dis* 2002; 35:219-227.

(328) Weber DJ, Rutala WA. Lessons from outbreaks associated with bronchoscopy. *Infect Control Hosp Epidemiol* 2001; 22:403-408.

(329) Government Publications TSOD. The Safety Health and Welfare at Work Act 2005. 2005.

(330) Gershon AS, McGeer A, Bayoumi AM, Raboud J, Yang J. Health care workers and the initiation of treatment for latent tuberculosis infection. *Clinical Infectious Diseases* 2004; 39(5):667-672.

(331) Rose AMC, Watson JM, Graham C, Nunn AJ, Drobniewski F, Ormerod LP et al. Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. *Thorax* 2001; 56:173-179.

(332) Department of Health and Children. Communicable disease screening for asylum seekers. 1-8. 2004.

(333) White MC, Tulsky JP, Portillo CJ, Menendez E, Cruz E, Goldenson J. Tuberculosis prevalence in an urban jail: 1994 and 1998. *International Journal of Tuberculosis and Lung Disease* 2001; 5:400-404.

(334) Jones TF, Craig AS, Valway SE, Woodley CL, Schaffner W. Transmission of tuberculosis in a jail. *Ann* 1999; 131:557-563.

(335) Koo DT, Baron RC, Rutherford GW. Transmission of *Mycobacterium tuberculosis* in a Californian state prison. *American Journal of Public Health* 1991; 87:279-282.

(336) MacIntyre CR, Kendig N, Kummer L, Birago S, Graham NM. Impact of tuberculosis control measures and crowding on the incidence of tuberculosis infection in Maryland prisons. *Clinical Infectious Diseases* 1997; 24:1060-1067.

(337) Cummings KC, Mohle-Boetani J, Royce SE, Chin DP. Movement of tuberculosis patients and the failure to complete antituberculosis treatment. *American Journal of Respiratory and Critical Care Medicine* 1998; 157:1249-1252.

(338) Capewell S, France AJ, Anderson M, Leitch AG. The diagnosis and management of tuberculosis in common hostel dwellers. *Tubercle* 1986; 67(2):125-131.

(339) Patel KR. Pulmonary tuberculosis in residents of lodging houses, night shelters and common hostels in Glasgow: a 5-year prospective survey. *British Journal of Diseases of the Chest* 1985; 79(1):60-66.

(340) Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance of homelessness, problem drug use and prison. *Thorax* 2007; 62:667-671.

(341) de Vries G, van Hest RA, Richardus JH. Impact of mobile radiographic screening on tuberculosis among drug users and homeless persons. *American Journal of Respiratory and Critical Care Medicine* 2007; 176(2):201-207.

(342) Centers for Disease Control and Prevention. Treating opportunistic infections among HIV infected adults and adolescents. *Morbidity and Mortality Weekly Report* 2004; 53(RR-15):1-112.

(343) Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. *Morbidity and Mortality Weekly Report* 2004; 53(RR-14): 1-92.

(344) World Health Organization: Stop TB Department, Department of HIV/AIDS, Department of Child and Adolescent Health and Development. TB/HIV. A clinical manual. Second ed. Geneva: World Health Organization; 2004.

(345) Pozniak AL, Miller RF, Lipman MC. BHIVA treatment guidelines for TB/HIV infection. 2005. London, British HIV Association.

(346) Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Archives of Internal Medicine* 2003; 163(9):1009-1021.

(347) Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency virus. An analysis using restriction fragment-length polymorphism. *New England Journal of Medicine* 1992; 326(4):231-235.

(348) Page KR, Chaisson RE, Godfrey-Faussett P. Tuberculosis HIV Co-infection: Epidemiology, Clinical Aspects, and Interventions. Tuberculosis: a comprehensive international approach. Third ed. New York, USA: Informa Healthcare; 2006. 371-416.

(349) Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. *American Journal of Respiratory and Critical Care Medicine* 1993; 148(5):1292-1297.

(350) Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS et al. Effect of *Mycobacterium tuberculosis* on HIV replication: role of immune activation. *Journal of immunology* 1996; 157(3):1271-1278.

(351) Goletti D, Weissman D, Jackson RW, Collins F, Kinter A, Fauci AS. The *in-vitro* induction of human immunodeficiency virus (HIV) replication in purified protein derivative-positive HIV-infected persons by recall antigen response to *Mycobacterium tuberculosis* is the result of a balance of the effects of endogenous interleukin-2 and proinflammatory and anti-inflammatory cytokines. *Journal of Infectious Diseases* 1998; 177(5):1332-1338.

(352) Mayanja-Kizza H, Johnson JL, Hirsch CS, Peters P, Surewicz K, Nalugwa G et al. Macrophage-activating cytokines in human immunodeficiency virus type-1 and uninfected patients with pulmonary tuberculosis. *Journal of Infectious Diseases* 2001; 183(12):1805-1809.

(353) Batungwanayo J, Taelman H, Bogaerts J, Allen S, Van dePerre P. Pulmonary tuberculosis in Kigali, Rwanda. Impact of human immunodeficiency virus infection on clinical and radiographic presentation. *American Review of Respiratory Disease* 1992; 146:53-56.

(354) Klein NC, Duncanson FP, Lennox TH, Pitta A, Cohen SC, Wormser GP. Use of mycobacterial smears in the diagnosis of pulmonary tuberculosis in AIDS/ARC patients. *Chest* 1989; 95:1190-1192.

(355) Hsieh SM, Hung CC, Chen MY, Hsueh PR, Chang SC, Luh KT. The role of tissue studies in facilitating early initiation of antimycobacterial treatment in AIDS patients with disseminated Mycobacterial disease. *International Journal of Tuberculosis and Lung Disease* 1999; 3:521-527.

(356) Relkin F, Aranda CP, Garay DM, Smith R, Berkowitz KA, Rom WN. Pleural tuberculosis and HIV infection. *Chest* 1994; 105:1338-1341.

(357) Shriner KA, Mathisen GE, Goetz MB. Comparison of mycobacterial lymphadenitis among persons infected with human immunodeficiency virus and seronegative controls. *Clinical Infectious Diseases* 1992; 15:601-605.

(358) Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. *New England Journal of Medicine* 1999; 340(5):367-373.

(359) Stout JE, Ratard R, Southwick KL, Hamilton CD. Epidemiology of human immunodeficiency testing among patients with tuberculosis in North Carolina. *Southern Medical Journal* 2002; 95(2):231-238.

(360) Bartlett JG, Gallant JE. Medical management of HIV infection 2001-2002. Baltimore: Johns Hopkins University, Division of Infectious Disease; 2001.

(361) Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA et al. Tuberculin and anergy testing in HIV-sero-positive and HIV sero-negative persons. Pulmonary complications of HIV infection study group. *Annals of Internal Medicine* 1993; 119:-185.

(362) Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell based assay: a prospective cohort study. *Lancet* 2004; 364:2196-2203.

(363) Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL et al. A controlled trial of isoniazid in person with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. *New England Journal of Medicine* 1997; 337:315-320.

(364) Moreno S, Miralles P, Diaz MD, Baraia J, Padilla B, Berenguer J et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival. *Archives of Internal Medicine* 1997; 157:1729-1734.

(365) Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. *New England Journal of Medicine* 1997; 337:80180-808.

(366) Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. *American Review of Respiratory Disease* 1991; 144:745-749.

(367) Centers for Disease Control and Prevention. Emerging infectious diseases. Tuberculosis morbidity - United States 1992. *Morbidity and Mortality Weekly Report* 1993; 42:696.

(368) Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City- turning the tide. *New England Journal of Medicine* 2007; 333:229-233.

(369) Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. *Morbidity and Mortality Weekly Report* 2002; 51(RR-8):1-17.

(370) Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. *Lancet* 2002; 359:2059-2064.

(371) Jones BE, Young SM, Antoniskis D, Davidson PT, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. *American Review of Respiratory Disease* 1993; 148:1292-1297.

(372) Santoro-Lopes G, de Pinho AM, Harrison LH, Schecter GF. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. *Clinical Infectious Diseases* 2002; 34:543-546.

(373) Churchyard GJ, Kleinschmidt I, Corbett EL, Murray J, Smit J, De Cock KM. Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. *International Journal of Tuberculosis and Lung Disease* 2000; 4:705-712.

(374) Murray J, Sonnenberg P, Shearer SC, Godfrey-Fausset P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. *American Journal of Critical Care Medicine* 1999; 159:733-740.

(375) Nunn P, Brindle R, Carpenter L, Odhiambo J, Wasunna K, Newnham R et al. Cohort of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (6-month) mortality. *American Review of Respiratory Disease* 1992; 146:849-854.

(376) Carvalho AC, DeRiemer K, Nunes ZB, Martins M, Comelli M, Marinoni A et al. Transmission of *Mycobacterium tuberculosis* to contacts of HIV-infected tuberculosis patients. *American Journal of Respiratory and Critical Care Medicine* 2001; 164(12):2166-2171.

(377) Cruciani M, Malena M, Bosco O, Gatti G, Serpelloni G. The impact of human immunodeficiency virus type 1 on infectiousness of tuberculosis: a meta-analysis. *Clinical Infectious Diseases* 2001; 33(11):1922-1930.

(378) Iseman D. Tuberculosis in relation to HIV and AIDS. A clinician's guide to tuberculosis. Philadelphia: Lipincott Williams and Wilkins; 2000. 199-252.

(379) The interdepartmental Working Group on Tuberculosis. The prevention and control of tuberculosis in the United Kingdom: UK guidance on the prevention and control of: 1 HIV-1 related tuberculosis; 2 drug resistant including multiple drug-resistant tuberculosis. 1998. Department of Health, UK.

(380) Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. *Science* 2005; 307(5707):223-227.

(381) Losi M et al. Use of a T-cell interferon-{gamma} release assay for the diagnosis of tuberculous pleurisy . *European Respiratory Journal* 2007; 30(6):1173-1179.

(382) Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. *Immunity* 2006; 24(1):105-117.